- Home
- software
- usa massachusetts
- genomics redefines the boundaries of fungal genomics
Refine by
Genomics Redefines The Boundaries Of Fungal Genomics Software In Usa Massachusetts
25 software items found
by:Frameshift Labs, Inc. based inBoston, MASSACHUSETTS (USA)
Mosaic is a collaborative platform for organizing, visualizing, and understanding genomic ...
by:TriNetX, LLC based inCambridge, MASSACHUSETTS (USA)
The full set of base analytics are enabled on every network, except for anonymous networks such as Linked, where HCO attribution is not shown. With Explore Cohort, review the prevalence of diagnoses, treatments, and procedures among your cohort, retrieve lab value means and standard deviations, and count instances of variants by genome. Use Criteria Analysis to rank order your query ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) of the human exome has the potential to identify pathogenic variants responsible for complex phenotypes associated with rare ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Metabolic disorders are a major cause of morbidity and mortality, representing a growing health concern worldwide. Over the last decade, substantial progress has been made in the discovery of genetic variants influencing a range of metabolic diseases.1 The advances in next generation sequencing (NGS) technologies have contributed to elucidation of the pathogenic role of variants associated with ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) has the potential to revolutionize the diagnosis and treatment of cancers and rare diseases but creates extremely large, complex, and noisy datasets for analysis. Without the right analytical technology, pinpointing causative variants and obtaining actionable insights from NGS data requires specialist skills, multiple resources, and considerable time. The ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Cardiac diseases are the #1 cause of death globally1,2. Genetic testing is frequently considered a key component of the clinical management process of inherited cardiac disorders, such as hypertrophic, dilated, and arrhythmogenic cardiomyopathies, aortopathies, and inherited arrhythmia syndromes3. This approach is typically reserved for patients with a confirmed or suspected diagnosis of an ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Alamut Visual Plus™ enables deep assessment of variants on a genomic scale, empowering clinical researchers to make accurate decisions for their data interpretation. Alamut Visual Plus™ is a full genome browser designed to help researchers investigate variations of the human genome. The software combines a wide set of external data with high-quality missense and splicing predictors in ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Clinical interpretation has been one of the most complex and time-consuming aspects of transforming genomic data into meaningful results, until ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Maximize your biologically actionable insights from small tumor samples with the SOPHiA DDM™ RNAtarget Technology end-to-end solutions. Gene fusions have been associated with various tumors and are recognized as valuable cancer biomarkers in cancer research1. Targeted RNA sequencing is recommended to maximize novel fusion detection by identifying transcribed and potentially actionable ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hematological tumors represent the fourth most frequent cancer type in the developed world. In addition to the continuously evolving clinical guidelines2, harnessing of all the available information when investigating hematological disorders into meaningful insights can be outdated, inaccurate, costly, and time-consuming. This ultimately risks limiting researchers’ productivity, thus ...
by:TriNetX, LLC based inCambridge, MASSACHUSETTS (USA)
Data sourced from the EHRs of U.S. healthcare organizations forms the foundation of this combined data asset, providing a rich clinical picture of patients from encounters with providers, lab results, procedures, medication orders, and genomics. Medical and pharmacy claims provide insight into a patient’s care before and after these encounters, regardless of provider. Pre-existing ...
by:PathAI, Inc. based inBoston, MASSACHUSETTS (USA)
PathExploreTM offers unprecedented spatial and cellular resolution of the tumor microenvironment (TME) from H&E images. PathExplore is an AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) with single-cell ...
by:Seven Bridges Genomics based inCharlestown, MASSACHUSETTS (USA)
The representation of the human reference genome as a linear haploid DNA sequence poses limitations when trying to incorporate the known genetic diversity of human populations. This has led to the development of graph-based references, able to naturally represent all polymorphisms, including insertions, deletions, and structural ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Most rare and inherited diseases have a neurological component, likely because more than 80% of human genes are expressed in the brain.1 Neurological disorders are multifactorial and heterogeneous, meaning that their genetic basis is often poorly understood. Indeed, only 30-50% of neurological disorders have a molecular genetic diagnosis.2 ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hereditary causes account for ∼10% of cancer cases, and an estimated 20% of cancer patients have a family history of cancer. Identification of an individual with a suspected hereditable cancer can lead to additional examinations and help formulate the most appropriate prevention strategies. Evaluating the predisposition to develop inherited cancer depends on the ability to characterize genes ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Genomic profiling is driving precision oncology. From targeted to comprehensive solutions, Next-Generation-Sequencing (NGS) offers the capacity to simultaneously analyze a select set of genes, regions, and biomarkers based on known involvement across solid tumor such as lung, colon, breast, melanoma, gastric, and ovarian cancers. However, as tests either expand or become more specialized, ...
by:Genuity Science based inBoston, MASSACHUSETTS (USA)
We are developing novel causal artificial intelligence and machine learning (AI/ML) and unconventional computing strategies to better understand human biology – and then apply these to deliver better medicine and improve health for people around the ...
by:Seven Bridges Genomics based inCharlestown, MASSACHUSETTS (USA)
The Seven Bridges Platform is a cloud-based environment for conducting bioinformatic analyses. It is a central hub for teams to store, analyze, and jointly interpret their bioinformatic data. The Platform co-locates analysis pipelines alongside the largest genomic datasets to optimize processing. It allocates storage and compute resources on demand, to meet the needs of ever-growing ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Confidently assess genetic variants predisposing to cancer. Hereditary causes account for ∼10% of cancer cases, and an estimated 20% of cancer patients have a family history of cancer.1 Identification of an individual with a suspected hereditable cancer can lead to additional examinations and help formulate the most appropriate prevention strategies. Evaluating the predisposition to develop ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Pioneering Innovation, Streamlining Adoption: We are pushing the boundaries of today’s liquid biopsy capabilities. Bring liquid biopsy to your lab with our streamlined DNA-only NGS workflow, taking you from cell-free DNA sample to comprehensive report in record time. Powered by state-of-the-art proprietary algorithms, the SOPHiA DDMTM Platform reveals deep genomic insights from cell-free ...